The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

The FDA accepts and grants priority review to Merck's sNDA for Welireg to treat advanced pheochromocytoma and paraganglioma.

About LITESPARK-015 LITESPARK-015 is an open-label, single-arm, multi-cohort Phase 2 trial (NCT04924075) evaluating the efficacy and safety of WELIREG monotherapy in patients with advanced PPGL ...

The US Food and Drug Administration (FDA) has accepted for priority review a supplemental new drug application (sNDA) for ...

The FDA has accepted the application for belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA ...

Welireg generated $139 million in sales during 2024’s third quarter and is the only approved HIF-2α inhibitor in the U.S. Merck’s application in PPGL is ... cases of the tumors are diagnosed ...

Rahway, New Jersey Tuesday, January 28, 2025, 10:00 Hrs [IST] ...

Jan. 28, 2025 — A new study shows that asymptomatic brain metastasis is more common in stage 4 breast cancer patients than previously believed. The study suggests that doctors may need to ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.

Jan. 30, 2025 — A new study shows that artificial intelligence (AI) can help doctors make better decisions when treating cancer. However, it also highlights challenges in how doctors and AI work ...